Loss of miR-126 is crucial to pancreatic cancer progression

Expert Review of Anticancer Therapy

Volumn 12, Issue 7, 2012, Pages 881-884

  Frampton, Adam E ^a   Krell, Jonathan ^a   Jacob, Jimmy ^a   Stebbing, Justin ^b   Castellano, Leandro ^a   Jiao, Long R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

ADAM9; EMT; epithelial to mesenchymal transition; metastasis; microRNA; miR 126; pancreatic ductal adenocarcinoma; PDAC

Indexed keywords

ADAM PROTEIN; MICRORNA 126; PROTEIN ADAM9; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE LOSS; HUMAN; MIGRATION INHIBITION; ONCOGENE; ONCOGENE CRK; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PROTEIN TARGETING; REVIEW; RNA ANALYSIS;

EID: 84864604837     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.67     Document Type: Review

References (22)

1. Hamada S, Satoh K, Fujibuchi W et al. miR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol. Cancer Res. 10(1), 3-10 (2012).
2. Funel N, Giovannetti E, Pollina LE et al. Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer. Expert Rev. Mol. Diag. 11(7), 695-701 (2011).
3. Jamieson N.B. Morran D.C. Morton J.P. et al. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma 18 2 534-545 2012.
4. Jamieson NB, Morran DC, Morton JP et al. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin. Cancer Res. 18(2), 534-545 (2012). 4 Kent OA, Chivukula RR, Mullendore M et al. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 24(24), 2754-2759 (2010).
5. Szafranska AE, Davison TS, John J et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26(30), 4442-4452 (2007).
6. Li A, Omura N, Hong S-M et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 70(13), 5226-5237 (2010).
7. Meister J, Schmidt MH. miR-126 and miR-126*: New players in cancer. ScientificWorldJournal 10, 2090-2100 (2010).
8. Jiao LR, Frampton AE, Jacob J et al. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PloS ONE 7(2), e32068 (2012).
9. Grutzmann R, Luttges J, Sipos B et al. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br. J. Cancer 90(5), 1053-1058 (2004).
10. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9(4), 265-273 (2009).
11. Cano CE, Motoo Y, Iovanna JL. Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. ScientificWorldJournal 10, 1947-1957 (2010).
12. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10(10), 704-714 (2009).
13. Li XM, Wang AM, Zhang J, Yi H. Down-regulation of miR-126 expression in colorectal cancer and its clinical significance. Med. Oncol. 28(4), 1054-1057 (2011).
14. Guo C, Sah JF, Beard L, Willson JKV, Markowitz SD, Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 47(11), 939-946 (2008).
15. Liu B, Peng XC, Zheng XL, Wang J, Qin YW. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer 66(2), 169-175 (2009).
16. Wong HH, Lemoine NR. Pancreatic cancer: Molecular pathogenesis and new therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 6(7), 412-422 (2009).
17. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: Determinants beyond seed pairing. Mol. Cell 27(1), 91-105 (2007).
18. Lal A, Navarro F, Maher CA et al. miR-24 inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to seedless 32UTR microRNA recognition elements. Mol. Cell 35(5), 610-625 (2009).
19. Li X, Shen Y, Ichikawa H, Antes T, Goldberg GS. Regulation of miRNA expression by Src and contact normalization: Effects on nonanchored cell growth and migration. Oncogene 28(48), 4272-4283 (2009).
20. Tavazoie SF, Alarcon C, Oskarsson T et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451(7175), 147-152 (2008).
21. Khew-Goodall Y, Goodall GJ. A microRNA that limits metastatic colonisation and endothelial recruitment. EMBO J. 31(4), 786-787 (2012).
22. Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 481(7380), 190-194 (2012).